Reference
National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia. Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Patients: Risk of Major Adverse Cardiovascular Events (MACE) and Malignancies [Excluding Non-Melanoma Skin Cancer (NMSC)] Internet Document : 31 Dec 2021. Available from: URL: https://npra.gov.my/index.php/en/component/content/article/426-english/safety-alerts-main/safety-alerts-2021/1527288-janus-kinase-jak-inhibitors-in-rheumatoid-arthritis-patients-risk-of-major-adverse-cardiovascular-events-mace-and-malignancies-excluding-non-melanoma-skin-cancer-nmsc-2.html?Itemid=1391
Rights and permissions
About this article
Cite this article
Janus kinase inhibitors in patients with RA: risk of MACE and cancer. Reactions Weekly 1889, 2 (2022). https://doi.org/10.1007/s40278-022-08681-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-08681-z